TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04700254

Intervention type: OTHER
Intervention: DASS questionnaire
Description: The DASS is a 42-item self report instrument designed to measure the three related negative emotional states of depression, anxiety and tension/stress

Intervention type: OTHER
Intervention: DASS questionnaire
Description: The DASS is a 42-item self report instrument designed to measure the three related negative emotional states of depression, anxiety and tension/stress

Intervention type: OTHER
Intervention: DASS questionnaire
Description: The DASS is a 42-item self report instrument designed to measure the three related negative emotional states of depression, anxiety and tension/stress

Intervention type: OTHER
Intervention: EAT-26 questionnaire
Description: The Eating Attitudes Test (EAT-26), is a self-report 26-item questionnaire of symptoms and concerns characteristic of eating disorders.

Intervention type: OTHER
Intervention: EAT-26 questionnaire
Description: The Eating Attitudes Test (EAT-26), is a self-report 26-item questionnaire of symptoms and concerns characteristic of eating disorders.

Intervention type: OTHER
Intervention: EAT-26 questionnaire
Description: The Eating Attitudes Test (EAT-26), is a self-report 26-item questionnaire of symptoms and concerns characteristic of eating disorders.
Study: NCT03149653

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ClinOleic (baseline)
Description: Lipid emulsion in pharmacy compounded all-in-one admixture

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ClinOleic (baseline)
Description: Lipid emulsion in pharmacy compounded all-in-one admixture

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ClinOleic + Omegaven
Description: Lipid emulsion in pharmacy compounded all-in-one admixture

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ClinOleic + Omegaven
Description: Lipid emulsion in pharmacy compounded all-in-one admixture

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lipoplus (baseline)
Description: Lipid emulsion in pharmacy compounded all-in-one admixture

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lipoplus (baseline)
Description: Lipid emulsion in pharmacy compounded all-in-one admixture

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lipoplus + Omegaven
Description: Lipid emulsion in pharmacy compounded all-in-one admixture

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lipoplus + Omegaven
Description: Lipid emulsion in pharmacy compounded all-in-one admixture

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SMOFlipid (baseline)
Description: Lipid emulsion in pharmacy compounded all-in-one admixture

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SMOFlipid (baseline)
Description: Lipid emulsion in pharmacy compounded all-in-one admixture

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SMOFlipid + Omegaven
Description: Lipid emulsion in pharmacy compounded all-in-one admixture

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SMOFlipid + Omegaven
Description: Lipid emulsion in pharmacy compounded all-in-one admixture
Study: NCT02496416

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aquatic Exercise Program
Description: The aquatic exercise program will consist of 45 minute classes held 3 days/week for 8 weeks (18 hours total). The program is based on guidelines provided by the National Multiple Sclerosis Society (NMSS) and will be led by an aquatic fitness instructor certified to teach individuals with MS at the YMCA in Scotch Plains-Fanwood. The exercises will focus on improving flexibility, balance and strength. Equipment such as water mitts, paddles, noodles and bands will be used to increase the level of difficulty as needed.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Stretching Program
Description: The stretching program will consist of 45 minute classes held 3 days/week for 8 weeks (18 hours total). The program is based on guidelines provided by the National Multiple Sclerosis Society (NMSS) and will be conducted online via a secure video-conferencing website.
Study: NCT03648658

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paracetamol 120Mg/5mL Oral Suspension
Description: The subjects will be treated with paracetamol in therapeutic doses, 15mg/kg/dose every six hour, with a maximum dosage of 1 g x 4 per day, for three consecutive days.
Study: NCT01037023

Intervention type: DRUG
Intervention: Topotecan
Description: patients administrated Topotecan according to the prescribing information
Study: NCT03968796

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Transcutaneous Electrical Nerve Stimulation (TENS)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Transcutaneous Electrical Nerve Stimulation (TENS)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sham Transcutaneous Electrical Nerve Stimulation (TENS)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sham Transcutaneous Electrical Nerve Stimulation (TENS)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Kinesio Taping
Study: NCT03602560

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: seladelpar 10 mg
Description: Seladelpar 10 mg for double-blind period. After completion of the 1-year double-blind period subjects will be offered the opportunity to enter an open label safety study. Subjects will continue the seladelpar dose (10 mg) received during the double-blinded study

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One capsule daily for double-blind period. After completion of the 1-year double-blind period subjects will be offered the opportunity to enter an open label long term safety study. Subjects on placebo will be re-randomized to initiate seladelpar at 5 or 10 mg once daily
Study: NCT00423787

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Ragweed MATA MPL
Description: 4 injections of increasing dose strength:~1. 300 SU/0.5 ml~2. 700 SU/0.5 ml~3. 2000 SU/0.5 ml~4. 6000 SU/0.5 ml
Study: NCT02096094

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bath with chlorhexidine
Description: Volunteers will be asked to perform full body bath with wipes with 2% chlorhexidine impregnation and with 0.15% chlorhexidine shampoo (for the head and genitalia) for 3 to 5 days. Each day the volunteer will answer a survey regarding side effects (skin reactions) and comfort related to the bath. At the end of the intervention, a skin culture to quantify skin colonization will be performed.
Study: NCT00909155

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Venlafaxine ERT
Description: Titrated to a minimum dose of 75mg. Further titration based on clinician assessment at followup visits. Intervention to continue through completion of study (180 days). Initial titration: Days 1-7: 37.5 mg; Days 7-14: 75 mg; Days 15-180: 75-300mg based on clinician assessment. Titration rate is a maximum of 75mg/7d.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluoxetine
Description: Titrated to a minimum dose of 20mg. Further titration based on clinician assessment at followup visits. Intervention to continue through completion of study (180 days). Initial titration: Days 1-7: 20mg; Days 7-14: 20mg; Days 15-180: 20-80mg based on clinician assessment. Titration rate is a maximum of 20mg/7d
Study: NCT03955094

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intubation via AMBU® AURAGAIN™
Description: Success rate of paediatric intubation through AMBU® AURAGAIN™
Study: NCT02920060

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous levetiracetam
Description: intravenous levetiracetam(30mg/kg bolus followed by 20mg/kg/dose IV 12 hourly).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium valproate
Description: intravenous sodium valproate(20mg/kg bolus followed by 10 mg/kg/dose IV 8hrly)
Study: NCT02382094

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bicalutamide

Intervention type: DRUG
Group type: OTHER
Intervention: Bicalutamide
Study: NCT03436173

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Description: Fluoxetine 10 mg/2.5 ml mixed with water

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Peppermint syrup
Description: Liquid peppermint syrup measured to the equivalent volume and mixed with water
Study: NCT00938730

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YM150
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YM150
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YM150
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YM150
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YM150
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YM150
Description: oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Warfarin
Description: oral
Study: NCT03359902

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous vagal nerve stimulation
Description: Non-invasive stimulation provided by transcutaneous electrical nerve stimulation device at 20Hz, 100 μs pulse width

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous vagal nerve stimulation
Description: Non-invasive stimulation provided by transcutaneous electrical nerve stimulation device at 20Hz, 100 μs pulse width

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham stimulation
Description: Sham stimulation will be performed using electrodes placed on earlobe

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham stimulation
Description: Sham stimulation will be performed using electrodes placed on earlobe
Study: NCT02964598

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Gamified intervention
Description: A new mobile application for assisting in sleep regulation, duration 4-6 weeks

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Gamified intervention
Description: A new mobile application for assisting in sleep regulation, duration 4-6 weeks

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep coaching
Description: A new personalized program, duration 4-6 weeks

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep coaching
Description: A new personalized program, duration 4-6 weeks

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bright light
Description: Morning bright light 10 000 lux maximum duration 4-6 weeks

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bright light
Description: Morning bright light 10 000 lux maximum duration 4-6 weeks

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bright light
Description: Morning bright light 10 000 lux maximum duration 4-6 weeks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control
Description: Minimal information on sleep timing and advancing the sleep rhythm

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Psychoeducation
Description: An extensive information platform in the internet created for this purpose
Study: NCT01852084

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: enVista® One-Piece Hydrophobic Acrylic Toric IOL
Description: Test lens having a toric cylinder power of either 1.25 diopters (D), 2.00 D, or 2.75 D

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: enVista control lens
Description: Spherical Control lens
Study: NCT00578357

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: personalized feedback intervention
Description: personalized feedback will be sent to participants after they complete and return self-help materials/questionnaires
Study: NCT03968796

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Kinesio Taping

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sham Kinesio Taping

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sham Kinesio Taping
Study: NCT01886768

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Double pledget nasal anesthesia (DPNA)
Description: By using a transnasal endoscope as a guide and a biopsy forceps, two gauze strips soaked with decongestant and anesthesia will be delivered to the middle meatus followed by the inferior meatus under real-time transnasal endoscopic guidance.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Single pledget nasal anesthesia (SPNA)
Description: Another randomized group of patients will also receive endoscopic-guided gauze pledgetting using a transnasal endoscope as a guide and a biopsy forceps. One gauze strip soaked with decongestant and anesthesia will be delivered to either the middle meatus or inferior meatus determined by anterior rhinoscopy.
Study: NCT02158182

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lactulose
Description: 30 ml by mouth three times daily until melena resolved, then adjusted to dose-response to obtain two to three soft stools. Duration of therapy: 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-ornithine L-aspartate
Description: 10 grams by intravenous way for 24 hours. Duration of therapy: 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifaximin
Description: 2 tablets (400mg) three times daily. Duration of therapy: 7 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (for lactulose) 30ml of dextrose solution by mouth three times daily, for 7 days.~Placebo (for L-ornithine L-aspartate) saline solution 500ml by intravenous way for 24 hours, for 7 days.~Placebo (for rifaximin) 2 dextrose tablets three times daily for 7 days.
Study: NCT04725708

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: procedure: cerebral oxygenation intervention
Description: During the surgery, cerebral oxygenation will be followed and intervention will be made to pH, PaO2, PaCO2, mean arterial pressure, hematocrit when necessary. In addition perfusion flow was maintained at or close to between 2.2-2.5 L/min/m2 . Perfusion pressure was adjusted using a phenylephrine infusion to maintain a mean arterial pressure of 50 to 70 mm Hg.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: procedure: cerebral oxygenation intervention
Description: During the surgery, cerebral oxygenation will be followed and intervention will be made to pH, PaO2, PaCO2, mean arterial pressure, hematocrit when necessary. In addition perfusion flow was maintained at or close to between 2.2-2.5 L/min/m2 . Perfusion pressure was adjusted using a phenylephrine infusion to maintain a mean arterial pressure of 50 to 70 mm Hg.
Study: NCT01364805

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous Vitamin C
Description: The first 5 study visits will all take place in the General Clinical Research Center (GCRC). During these visits you will receive IV doses of Vitamin C. The dose of Vitamin C will be started at 25 grams and may be increased up to 125 grams over a two week period. There may be changes in the amount of Vitamin C that you receive based on your blood test levels. The study staff will go over this in more detail with you. The amount of fluid you receive depends on the dose and can be from 2 1/3 cups to 5 cups.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Participants receive dexamethasone 10 mg as pretreatment antiemetic; may be given ondansetron, granisetron, or dolasetron, per oncologist. Gemcitibane 1,000mg/m2 IV over 30 minutes Q 21 days. Cycle of treatment: infusions once weekly for 2 consecutive weeks followed by 1 week of rest to continue treatment schedule until they experience disease progression or unacceptable toxicity. CR, PR or SD: treatment will be continued for at least 6 cycles. Discontinuation of therapy may be considered if agreed upon by the participant and oncologist. Dose Modifications: If the patient experiences more than one toxicity, each requiring a dose reduction, follow the guidelines that give the largest dose reduction for the drug. Subsequent doses can be adjusted to as low as 500 mg/m2 for gemcitabine.
Study: NCT03659006

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Biological Collection
Description: Blood sampling on catheter and CSF sampling from VDE, multimodal MRI at D42 and D365, Neurological and neuropsychological evaluation at one year
Study: NCT00413764

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tibolone
Description: tibolone (2.5 mg) over 24 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: estradiol-norethisterone
Description: transdermal continuous combined E2-NETA (estradiol-norethisterone 50/140 mcg) over 24 weeks
Study: NCT03550625

Intervention type: DIAGNOSTIC_TEST
Intervention: Computer program
Description: No study specific intervention. Still images of polyps are collected. Histopathological reports of the resected polyps will be evaluated in order to create a computer program.
Study: NCT01861262

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Measurement of StO2
Description: The procedure is a measurement and non-invasive monitoring system of percentage of oxygen saturation of haemoglobin in tissues using infrared technology. The system used in the study is the tissue oxygenation monitor InSpectraTM StO2 Spot Check, Model 300 consisting of a clamp applied to the base of the thumb of the patient.
Study: NCT02516657

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liraglutide
Description: Liraglutide 0.6 mg
Study: NCT01723748

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: genotropin
Description: iii) intravenous exogenous bolus of GH (0.5 mg) followed by muscle and fat biopsies.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: genotropin
Description: iii) intravenous exogenous bolus of GH (0.5 mg) followed by muscle and fat biopsies.
Study: NCT04901156

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 1Hz inhibitory rTMS
Description: 20 minutes of 1Hz (1200 pulses) repetitive transcranial magnetic stimulation (rTMS) applied by Magstim Rapid 2 stimulator equipped with an airfilm figure-8 coil
Study: NCT03478397

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Multicomponent mHealth Intervention
Description: Women with HPV self-collected tests will receive a multicomponent intervention which includes SMS text messages to remind them to attend triage. In addition, CHWs will receive reminders via e-mails to contact women if after 60 days from the HPV-results HPV+ they have not performed triage
Study: NCT00423787

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ragweed MATA MPL
Description: 4 injections of increasing dose strength:~1. 300 SU/0.5 ml~2. 700 SU/0.5 ml~3. 2000 SU/0.5 ml~4. 6000 SU/0.5 ml
Study: NCT02216812

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 500 mg vitamin c, 1 pill per day for 6 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 1 placebo pill for 6 weeks
Study: NCT03470727

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Citrate dialysate
Description: Change form acetate to citrate dialysate
Study: NCT03610529

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CardioSenseSystem
Description: CardioSensySystem is a novel wireless ECG monitoring system developed by Novosense AB for monitoring of ECG in health care departments.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Philips Intellivue
Description: Philips Intellivue in an established ECG monitoring system used at the clinical investigational device.
Study: NCT03387488

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: StingrayTM, Medtronic®
Description: Video- assisted pericardioscopic surgery for implanting epimyocardial pacemaker lead model 09090, Medtronic®
Study: NCT02337231

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: soybean oil and borage oil
Description: Compare the capacity of humans with GG, GT and TT genotypes at rs174537 taking soybean and borage oils to metabolize medium chain PUFAs.

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: soybean oil and borage oil
Description: Compare the capacity of humans with GG, GT and TT genotypes at rs174537 taking soybean and borage oils to metabolize medium chain PUFAs.

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: soybean oil and borage oil
Description: Compare the capacity of humans with GG, GT and TT genotypes at rs174537 taking soybean and borage oils to metabolize medium chain PUFAs.
Study: NCT01659879

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multimedia information
Study: NCT04826653

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Suture removal
Description: Suture removal after coronally advanced flap plus a connective tissue graft

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Suture removal
Description: Suture removal after coronally advanced flap plus a connective tissue graft
Study: NCT04901156

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multi-Modality Aphasia Therapy (M-MAT)
Description: Participants receive 3.5 hours of intensive speech therapy in small groups delivered by a blinded speech language pathologist and therapy assistant. The objective of M-MAT is to improve word production through shaping of responses (ie. Gradually increasing complexity of spoken targets towards eventual mastery) and social-mediated repetitive practice. Therapists use game-based interactive tasks and rich multi-modal cueing (gestures, written words, drawing, reading words) to improve spoken production and oral communication.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Multi-Modality Aphasia Therapy (M-MAT)
Description: Participants receive 3.5 hours of intensive speech therapy in small groups delivered by a blinded speech language pathologist and therapy assistant. The objective of M-MAT is to improve word production through shaping of responses (ie. Gradually increasing complexity of spoken targets towards eventual mastery) and social-mediated repetitive practice. Therapists use game-based interactive tasks and rich multi-modal cueing (gestures, written words, drawing, reading words) to improve spoken production and oral communication.
Study: NCT04826653

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Suture removal
Description: Suture removal after coronally advanced flap plus a connective tissue graft
Study: NCT00724477

Intervention type: DRUG
Intervention: INEGY
Description: Ezetimibe 10mg - Simvastatine 20 mg or 40 mg; Tablet - OD; Patient currently treated for INEGY for at least 4 weeks
Study: NCT04901156

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: 1Hz sham rTMS
Description: 20 minutes of 1Hz (1200 pulses) repetitive transcranial magnetic stimulation (rTMS) applied by Magstim Rapid 2 stimulator equipped with an airfilm figure-8 sham coil.
Study: NCT02139956

Intervention type: DEVICE
Intervention: ultrasonography
Description: open

Intervention type: DEVICE
Intervention: ultrasonography
Description: open